UEGweek 2025

New molecules in moderate to severe UC: obefazimod &…

IL-23 inhibition: sc is nice, oral is better ?!

A new oral α4β7 integrin inhibitor - more questions…

AI AI captain! - AI improves histological diagnostics

If it helps, can we stop it? Drug withdrawel in IBD

Are JAK inhibitors better than their reputation?

Pregnancy and family planning in IBD

Complete disease clearence - the quest for the optimal…

A new oral inhibitor is changing the IL-23 landscape?

Timing is everything - surgical intervention in CD

JAKis may be safer than you probably think they are!

Efficacy of sc induction with guselkumab therapy in UC

Do biologics need an iv induction?

Finally time to stop the automatic continuation of…

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Effektivität der s.c. Induktion mit Guselkumab bei UC

T2T nella CU – prime evidenze retrospettive

Patients with early Crohn’s disease on adalimumab: can…

Injecting in fistulas: the never ending story?

Early treatment with adalimumab does not allow for…

Can we stop Adalimumab in CD patients achieving…

To stop or not to stop? That is the question (in…

Efficacy of Guselkumab in CD patients who lost response…

Therapy sequence: guselkumab is possible after…

Is it possible to stop anti-TNF treatment in early CD…

Perianal CD - it's associated with low infliximab…

Efficacy of guselkumab in patients with inadequate…

10 lat po badaniu LIR!C – aktualizacja danych o…

Czy przerywać skuteczne leczenie u pacjentów z chorobą…

Possiamo sospendere Adalimumab in pazienti affetti da…

הזרקת תאים לפיסטולה במחלת קרוהן- הסיפור שאינו נגמר?

Ασθενείς με πρόσφατη έναρξη νόσου του Crohn σε…

Therapiesequenz: Guselkumab nach Ustekinumab-Versagen…

Peut-on arrêter un anti-TNF dans la maladie de Crohn…

B-cell depletion in refractory ulcerative colitis –…

Go for oral anti-α4β7!

CAR-T cells in refractory UC – a new option for the…

Obefazimod - a new mechanism of action for the…

Icotrokina - a new oral drug for blocking IL-23

IL-23 blockade now also oral

B-Zell-Depletion bei refraktärer Colitis Ulcerosa -…

Obefazimod - Une nouvelle classe thérapeutique pour la…

Les cellules CAR-T dans la RCH réfractaire – une…

IL-23 Blockade jetzt auch oral

Mufemilast, αναστολέας της PDE4, για θεραπεία από του…

Etrasimod in mild to moderate UC

Histo-endoscopic endpoint in long-term extension of…

Short-term (8 weeks) efficacy & safety of obefazimod in…

Obefazimod induction therapy is effective and well…

Real-world short-term efficacy and safety of…

Long term persistence of ustekinumab in Real-Life…

Efectividad y seguridad en vida real a corto plazo de…

Etrasimod nella colite ulcerosa da lieve a moderata

Obefazimod-Induktionstherapie ist effektiv und gut…

Μακροχρόνια αποτελεσματικότητα της ουστεκινουμάμπης σε…

JAK-Inhibitoren sind vielleicht sicherer als Sie…

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Eficacia y seguridad a corto plazo (8 semanas) de…

Guselkumab sc in crohn’s disease with inadequate…

Ustekinumab in perianal Crohn’s disease

Dane typu real-life a badania kliniczne risankizumabu w…

Guselkumab sc en enfermedad de crohn con respuesta…

Looking for the black sheep pathways

Sigmoid volvulus: an old problem, still waiting for…

Real-life vs clinical trials IBD patients access to…

Vedolizumab - another option for JAKi-induced…

When nanoparticles calm down celiac-specific T-cells

AI-endoscopy ready - is it a game changer?

IBD outcome in a large national cohort from spain

Selection criteria for randomized clinical trials in…

IUS as a patient- and environmental-friendly tool in…

Let's go green! ecological effect of patient monitoring

Reassuring safety signals of JAKis in pregnant IBD…

JAKis and pregnany in IBD

Steroid-sparing effect of upfront Vedolizumab in…

New insights from the GEM trail

Eosinophile Ösophagitis ist kein Risikofaktor für ein…

Auf der Suche nach den schwarzen Pathway-Schafen

Co ma wspólnego USG jelit w IBD z ekologią?

Vedolizumab - eine zusätzliche Therapieoption bei…

Wenn Nanopartikel zöliakiespezifische T-Zellen…

פתלת הפרשדון....בעיה מוכרת שעדין מחכה לפתרון

Risparmio di steroidi in pazienti con colite indotta da…

Verso il verde! L’impatto ecologico del monitoraggio…

Segnali si sicurezza rassicuranti in donne affette da…

Critères de sélection des essais cliniques randomisés…

Πρόσβαση σε προχωρημένες θεραπείες καθημερινών ασθενών…